



Selection of Effective Therapies Using Three-Dimensional *in vitro* Modeling of Chondrosarcoma

Ieva Palubeckaitė¹, Sanne Venneker¹, Inge H. Briaire-de Bruijn¹, Brendy E. van den Akker¹, Augustinus D. Krol², Hans Gelderblom³ and Judith V. M. G. Bovée^{1*}

¹ Department of Pathology, Leiden University Medical Center, Leiden, Netherlands, ² Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands, ³ Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

OPEN ACCESS

Edited by:

Yong Teng,
Augusta University, United States

Reviewed by:

Lixia Gao,
Chongqing University of Arts and
Sciences, China
Isidro Machado,
Instituto Valenciano de
Oncología, Spain
Maria Vinci,
Bambino Gesù Children Hospital
(IRCCS), Italy

*Correspondence:

Judith V. M. G. Bovée
j.v.m.g.bovee@lumc.nl

Specialty section:

This article was submitted to
Molecular Diagnostics and
Therapeutics,
a section of the journal
Frontiers in Molecular Biosciences

Received: 27 May 2020

Accepted: 30 November 2020

Published: 21 December 2020

Citation:

Palubeckaitė I, Venneker S,
Briaire-de Bruijn IH, van den Akker BE,
Krol AD, Gelderblom H and
Bovée JVMG (2020) Selection of
Effective Therapies Using
Three-Dimensional *in vitro* Modeling of
Chondrosarcoma.
Front. Mol. Biosci. 7:566291.
doi: 10.3389/fmolb.2020.566291

Purpose: Chondrosarcomas are a group of cartilaginous malignant neoplasms characterized by the deposition of chondrogenic extracellular matrix. Surgical resection is currently the only curative treatment option, due to their high resistance to conventional chemotherapy and radiotherapy. Novel therapeutic treatment options may improve outcome. Predominantly used cell line monolayer *in vitro* models lack *in vivo* complexity, such as the presence of extracellular matrix, and differing oxygen access. Hence, we aimed to improve pre-clinical chondrosarcoma research by developing an alginate-based 3D cell culture model.

Method: An alginate scaffold was applied to generate spheroids of three chondrosarcoma cell lines (CH2879, JJ012, SW1353). Morphological, histological and immunohistochemical assessment of the spheroids were used to characterize the chondrosarcoma model. Presto blue assay, morphological and immunohistochemical assessment were applied to assess spheroid response to a panel of chemotherapeutics and targeted therapies, which was compared to conventional 2D monolayer models. Synergistic effect of doxorubicin and ABT-737 (Bcl-2 inhibitor) was compared between monolayer and spheroid models using excess over Bliss. A 3D colony formation assay was developed for assessment of radiotherapy response.

Results: Chondrosarcoma spheroids produced chondrogenic matrix and remained proliferative after 2 weeks of culture. When treated with chemotherapeutics, the spheroids were more resistant than their monolayer counterparts, in line with animal models and clinical data. Moreover, for sapanisertib (mTOR inhibitor) treatment, a recovery in chondrosarcoma growth, previously observed in mice models, was also observed using long-term treatment. Morphological assessment was useful in the case of YM-155 (survivin inhibitor) treatment where a fraction of the spheroids underwent cell death, however a large fraction remained proliferative and unaffected. Synergy was less pronounced in 3D compared to 2D. A 3D clonogenic assay confirmed increased resistance to radiotherapy in 3D chondrosarcoma spheroids.

Conclusion: We demonstrate that the chondrosarcoma alginate spheroid model is more representative of chondrosarcoma *in vivo* and should be used instead of the

monolayer model for therapy testing. Improved selection at *in vitro* stage of therapeutic testing will increase the amount of information available for experimental design of *in vivo* animal testing and later, clinical stages. This can potentially lead to increased likelihood of approval and success at clinical trials.

Keywords: chondrosarcoma, 3D cell culture, chemotherapy, radiotherapy, clonal spheroids, sarcoma, *in vitro* model

INTRODUCTION

Chondrosarcomas are a group of malignant cartilaginous neoplasms, which account for around 20% of bone sarcomas, making them the second most common primary bone malignancy after osteosarcoma (Hogendoorn et al., 2013). The hallmark of these tumors is the deposition of extracellular matrix rich in glycosaminoglycans and collagen II. Likelihood of metastasis is best predicted by the histological grade, as an atypical cartilaginous tumor/chondrosarcoma grade I is locally aggressive but rarely metastasizes while grade III chondrosarcomas have a high metastatic rate (32–71%) and poor 10-year survival rate (26–55%) (Angelini et al., 2012; Fromm et al., 2018; van Praag et al., 2018; Bovée et al., 2020). Conventional chemotherapy and radiotherapy have very limited efficacy in patients with advanced chondrosarcoma and surgical resection is currently the only curative treatment option (Angelini et al., 2012; Van Maldegem et al., 2014). Presently there is a large variety in the treatments used in order to attempt to improve survival (van Maldegem et al., 2019). A fraction of patients are managed with drugs which have shown activity in other soft-tissue and bone sarcomas, without any previous pre-clinical information on their efficacy in chondrosarcoma (Italiano et al., 2013). Its rareness, and therefore the lack of interest from industry, hamper the design and conduct of clinical trials for these patients (Miwa et al., 2019). There is an urgent need for more representative pre-clinical chondrosarcoma models to select therapeutic strategies that might be beneficial for patients.

At present, ~10 chondrosarcoma cell lines are available worldwide. These cell lines essentially reflect the heterogeneity of this tumor type, consisting of different subtypes, grades and mutation status (van Oosterwijk et al., 2012a; de Jong et al., 2016a). Cell lines in conventional two-dimensional (2D) monolayer culture can be easily used for high throughput drug screens, and this has revealed several compounds and combinations that might be beneficial for chondrosarcoma patients, including ABT-737 (Bcl-2 inhibitor) in combination with doxorubicin (van Oosterwijk et al., 2012b), YM-155

(Survivin inhibitor) (de Jong et al., 2016b), sapanisertib (mTOR inhibitor) (Addie et al., 2019), as well as radiotherapy (de Jong et al., 2019; Venneker et al., 2019).

However, the limitation of the use of cell lines in standard 2D culture is their restricted representability, as they lack the spatial organization, architecture and extracellular matrix that is characteristic of chondrosarcoma *in vivo* (Bovée et al., 2020). Moreover, pathway activity is altered during culture, for instance we previously showed upregulation of IGF1R expression in CH2879 cell line in 2D culture, while this was not seen in three-dimensional (3D) cultures, nor in the corresponding primary tumor (Peterse et al., 2016). Therefore, cell lines in 2D might not respond to therapy in the way cells do *in vivo*.

A common approach to improve the representability at the *in vitro* testing stage is to create 3D cell culture models. These mimic the natural organization of tissues more closely, which is especially relevant for tumors in which the spatial organization, architecture and interaction with the extracellular matrix are critical. These include chondrosarcoma, where the extracellular matrix is the defining factor, and by some even hypothesized to be involved in chemotherapy resistance (Bovée et al., 2010). Many different methods exist for the creation of 3D cell cultures of sarcoma including attachment prevention, embedded scaffold and bioreactor techniques. Each has advantages and disadvantages for sarcoma research (Colella et al., 2018).

To develop a 3D spheroid culture model for chondrosarcoma, we chose to use a biocompatible, plant derived scaffold, alginate hydrogel (Lee and Mooney, 2012; Lhuissier et al., 2017). Alginate hydrogel polymerises rapidly in the presence of divalent ions, such as Ca²⁺, therefore can be used for entrapment of single cells, which subsequently grow out into clonal spheroids. As the cells are embedded within a scaffold system, they receive physiological mechanical strain, are able to grow in three dimensions and deposit extracellular matrix (ECM) which will then remain within their surroundings. Alginate scaffolds are also suitable for drug treatment of cultures, as the pore size achieved is typically 5–200 nm and small soluble molecules are able to diffuse freely (Ching et al., 2017).

In this study, alginate chondrosarcoma spheroids were shown to produce extracellular matrix, similar to tumors *in vivo*, and were used for short and long-term drug testing, including assessment of synergy. Drug response within the model was monitored using cell viability assays as well as histological analysis and the model was additionally used to evaluate radiation sensitivity using a 3D colony formation assay.

Abbreviations: 2D, Two dimensional; 3D, Three-dimensional; DMSO, Dimethyl sulfoxide; ECM, Extracellular matrix; FBS, Fetal bovine serum; GR50, Half maximal growth rate inhibitory concentration; H&E, Hematoxylin and Eosin; IC50, Half maximal inhibitory concentration; IDH, Isocitrate dehydrogenase; IMRT, Intensity-modulated radiation therapy; MCTS, Multicellular tumor spheroids; mut, mutant; PBS, Phosphate buffered saline; PBT, Proton-beam therapy; PFS, Progression-free survival; SF, Surviving fraction; SRS, Stereotactic radiosurgery; wt, wild type.

MATERIALS AND METHODS

Cell Culture

CH2879 (Grade III, *IDH1*: G105G (wt), *p53*: wt) (Gil-Benso et al., 2003), JJ012 (Grade II, *IDH1*: R132G mut, *p53*: G199V mut) (Jagasia et al., 1996; Scully et al., 2000) and SW1353 (Grade II, *IDH2*: R172S mut, *p53*: V203L mut) (ATCC, Manassas, USA) conventional chondrosarcoma cell lines were cultured in RPMI 1,640 medium (Life Technologies Limited, Paisley, UK) containing 10% fetal bovine serum (FBS) and 50 U/ml penicillin and 50 µg/mL streptomycin (Life Technologies Limited) (Pansuriya et al., 2011; de Jong et al., 2016b). They were maintained in a humidified atmosphere containing 5% CO₂ at 37°C. Short tandem repeat analysis was performed before and after completion of experiments to confirm identity of the cell lines by using the Cell ID Gene Print 10 system (Promega Benelux BV, Leiden, The Netherlands). Mycoplasma negativity was confirmed on a regular basis. The SJS-1, also referred to as OSA, (ATCC) osteosarcoma cell line was also cultured identically for use as a negative control for histological stains.

3D Cell Culture

Following expansion in a monolayer, cell lines were suspended in 1.2% (w/v) medium viscosity alginate (Sigma-Aldrich, Darmstadt, Germany) in 0.15 M NaCl at 1×10^6 cell/mL density to generate spheroids (~14,140 cells/bead). Concentrations of around 1% w/v alginate were deemed optimal for cartilage-orientated *in vitro* and *in vivo* applications by several groups (Heiligenstein et al., 2011; Rey-Rico et al., 2016). Alginate beads were formed by dropping the cellular suspension in 1.2% (w/v) alginate/0.15 M NaCl (Sigma-Aldrich) through a 19-gauge needle into 0.2 M CaCl₂ solution (Sigma-Aldrich). After incubation at 37°C for 10 min, alginate beads were washed twice with 0.15 M NaCl and washed twice in DMEM/F12 (Life Technologies Limited) complete media before being placed in RPMI medium overnight. The medium was replaced to DMEM/F12 medium where possible due to the alginate breakdown properties of phosphate buffer within RPMI medium (Lee and Palsson, 1990). The transition from RPMI to DMEM culture was made on the second day of culture in 3D to minimize transitioning stress on the cells. Preliminary tests were performed to determine the best time to transition the medium; before, during or after 3D cell culture establishment. Changing medium to DMEM 24 h after 3D cell culture was found to be the least disturbing for cell growth. The cells were cultured in DMEM/F12 for a maximum of 17 days.

Histological Staining

Day 3, 7, and 14 spheroids were fixed using 10% neutral buffered formalin, dehydrated and paraffin embedded. Sections were produced (4 µm) and, after deparaffinisation and rehydration, were stained with hematoxylin and eosin (H&E), using the Leica ST5020-CV5030 Stainer Integrated Workstation (Leica Biosystems, Amsterdam, The Netherlands), for morphological assessment by an expert bone tumor pathologist (JVMGB). Serial sections were stained with Richardson's toluidine blue or alcian blue solution, for assessment of glycosaminoglycan production; slides were incubated in boiling 10 mM citrate buffer (pH 6) for

10 minutes in order to remove the alginate scaffold, which is stained very strongly with both stains. After cooling and washing in dH₂O, sections were incubated in toluidine blue solution (1:32 diluted in dH₂O) for 5 min or incubated (30 min) in alcian blue solution (pH 2.5, RT). Excess dye on toluidine blue stained samples was removed in dH₂O and the slides were dried at 58°C for 30 min or until fully dry, before mounting. Alcian blue stained samples were washed in running tap water (2 min), rinsed in dH₂O, counterstained with nuclear fast red (5 min), dehydrated, cleared and mounted. SJS-1 cell line spheroids were stained as a negative control. For comparison to 2D, cell lines cultured in 2D were trypsinised, formalin fixed (30 min) and pre-embedded using the cytoblock system (7401150, Thermo Scientific, USA). Then the samples were dehydrated and paraffin embedded for sectioning. For comparison to chondrosarcoma *in vivo*, three high grade chondrosarcomas were retrieved from the archives of the Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. Tumor samples were fully anonymized according to the ethical guidelines described in "Code for Proper Secondary Use of Human Tissue in The Netherlands" of the Dutch Federation of Medical Scientific Societies.

Immunohistochemistry

Four micrometer paraffin embedded sample sections were deparaffinized in xylene and rehydrated with a series of gradient ethanol to water. For Ki-67 [anti-Ki-67 D2H10 rabbit monoclonal (1:1600)] (9027S, Cell Signaling, Massachusetts, USA), IGF1R [anti-IGF1R 111A9 rabbit monoclonal (1:2000)] (3018, Cell Signaling), activated caspase-3 [anti-activated caspase-3 rabbit polyclonal (1:1600)] (9661S, Cell Signaling), and phospho-S6 [anti-phospho-S6 ribosomal (2F9) rabbit monoclonal (1:400)] (4856S, Cell Signaling) detection heated antigen retrieval was performed by incubating slides in boiling 10 mM citrate buffer (pH 6) for 10 min and letting the solution cool down for 2 h. For Collagen type II [anti-collagen II rabbit polyclonal (1:200)] (34712, Abcam, Cambridge, United Kingdom) detection enzymatic antigen retrieval was performed via incubation in proteinase K (5 µL/mL) (3 min, RT) (Roche) followed by an incubation with hyaluronidase (5 mg/mL) (Sigma-Aldrich) (30 min, 37°C). Endogenous peroxidase was blocked by pre-incubation in H₂O₂ (0.3%) for 20 min and 5% non-fat milk solution was additionally used for the anti-collagen II primary antibody. Slides were incubated with the primary antibodies overnight at 4°C. Slides were incubated in biotin-free poly-HRP anti-Mouse/Rabbit IgG secondary antibody for 30 min (VWRKDPVO110HRP, VWR International, Amsterdam, The Netherlands). The signal was then visualized by incubation in DAB+ Chromogen for 10 min (K3468, Dako, Carpinteria, USA). The slides were counterstained in hematoxylin for 20 s, dehydrated and mounted for scanning using a Panoramic 250 Flash III scanner (3D Histech, Cheshire, UK) using a 40× magnification. Positive and negative controls were used for each antibody for quality control of the experiment.

The scanned IHC samples were scored using QuPath open-source software (Bankhead et al., 2017). All scoring was performed on a representative area spanning at least three biological replicates (beads). Scoring of Ki-67 was performed

using the software positive cell detection tool to determine the percentage of positive nuclei among the total number of nuclei within an area larger than $800,000 \mu\text{m}^2$. Scoring of activated caspase-3 staining was performed by manual counting of percentage of positive cells within an area larger than $600,000 \mu\text{m}^2$. Scoring of IGF1R was performed as previously published for 2D cells and tissue, based on overall intensity within an area larger than $700,000 \mu\text{m}^2$ (Peterse et al., 2016). Scoring of collagen II and pS6 was performed by scoring slides by percentage of positive spheroids within an area larger than $900,000 \mu\text{m}^2$. In this case a spheroid was termed positive if at least one area within the spheroid was calculated positive using the software positive cell detection tool. Setting the software detection threshold ensured reduction in observation variability. Samples were collected over at least three separate experiments and areas counted were from at least three replicates.

Assessment of Response to Antineoplastic Agents

Dose-response curves were generated for the three cell lines in 2D as well as 3D, keeping within 15 passages throughout the experiment. After trypsinisation, 2D cultured cells were seeded in 96-well plates at 7,000 (CH2879) or 3,000 (JJ012, SW1353) cells per well and left to adhere for 24 h. Treatment duration for 2D cultures was 72 h. In the case of 3D cell cultures, day 14 spheroids were used for 72 h treatment measurements and day 1 spheroids were used for 14 day treatments, including a measurement at 8 days (after 7 days of treatment) and a second dose at day 8.

Compounds were selected based on previous results (van Oosterwijk et al., 2011; de Jong et al., 2016b, 2018, 2019; Addie et al., 2019; Venneker et al., 2019). Doxorubicin and cisplatin were obtained from the in-house hospital pharmacy in a 0.9% (w/v) NaCl solution. ABT-737 (Bcl-2 inhibitor) (S1002, Selleckchem, Houston, TX, USA), AGI-5198 (mutant-IDH1 inhibitor) (14624, Cayman Chemical, Ann Arbor, MI, USA) YM155 (survivin inhibitor) (S1130, Selleckchem) and sapanisertib (mTOR inhibitor) (S2811, Selleckchem) were dissolved in DMSO according to the manufacturer's instructions.

After treatment, the medium was removed, wells were washed with medium and cell viability was determined using the PrestoBlue viability reagent (Invitrogen, Life-Technologies, Scotland, UK) according to the manufacturer's instructions. Plates were then incubated at 37°C for 1 h for monolayer cultures, one and a half hours for CH2879 and JJ012 spheroid cultures and 3 h for SW1353 spheroid cultures. Fluorescence was measured with an excitation/emission wavelength of 560/590 nm Victor3V 1420 multilabel counter (Perkin Elmer, Hamburg, Germany). Selected treated samples were processed for sectioning and histological and IHC staining.

Histological staining was also performed on select treated cultures. These were stained with H&E and the colony number was counted within a representative area spanning at least three biological replicates (beads).

The drug concentration which inhibited cell viability by 50% (IC_{50}) was determined using Prism software version 7.02 after normalization to untreated control samples. A Grubbs' test was

used to remove outliers from the dataset. Experiments were performed at least three times in triplicate. A Welch's ANOVA test was used to determine significant differences between the IC_{50} values obtained from 2D and 3D cultures. A *post-hoc* Dunnett's T3 multiple comparisons test was then performed for comparison of individual cell line results in 2D and 3D.

Assessment of Drug Synergy

Increasing concentrations of doxorubicin were used to treat the chondrosarcoma spheroid cultures in combination with $3.16 \mu\text{M}$ ABT-737 as this drug combination has demonstrated synergy in previously published monolayer models (van Oosterwijk et al., 2012b). The Bliss independence model ($C = A + B - A \times B$) was used to predict synergy, in which C represents the combined effect and A and B represent single agent effects (Borisy et al., 2003).

Assessment of Radiation Therapy Response

One day old spheroids were used for radiation treatment experiments. Five alginate beads per well were transferred to a 12-well plate. Increasing doses (0–6 Gy) of γ -radiation, using a ^{137}C source (YXLON, Comet Technologies, Shelton, USA), were applied to culture plates containing cell seeded alginate beads. These were cultured for 14 days, with a medium refresh at 7 days, formalin fixed using 10% formalin, dehydrated and paraffin embedded. The samples were then sectioned, stained using H&E, and the spheroid colony number and area, within an area of 3 mm^2 , was assessed using QuPath open source software (Bankhead et al., 2017). All counts were performed on a representative area spanning at least three biological replicates (beads).

RESULTS

Chondrosarcoma Cells Cultured Within an Alginate Model Display a Phenotype Closer to That of Chondrosarcoma *in vivo*

All cell lines cultured in alginate beads formed chondrosarcoma spheroids ranging from 50 to $156 \mu\text{m}$ diameter by 14 days of culture with an average diameter of $76 \mu\text{m}$. All spheroids displayed extracellular matrix deposition, as confirmed by toluidine blue and alcian blue staining (**Figure 1A**), while the osteosarcoma cell line (SJS-1) spheroid that served as control was negative as well as the cell lines cultured in 2D (**Supplementary Figures 1, 2**). Glycosaminoglycans were deposited throughout the spheroids and concentrated around the edges. Thus, in the alginate model, chondrosarcoma cells show some differentiation, as they produce extracellular matrix, similar to chondrosarcoma *in vivo* (**Supplementary Figure 1**). Collagen II was also expressed in the extracellular matrix and was stable or increased over time (**Figures 1B,C**). These features are hallmarks of chondrosarcoma but known to be absent in 2D culture (Scully et al., 2000; Gil-Benso et al., 2003; Gebauer et al., 2005) which we confirmed as the three cell lines cultured in 2D lacked glycosaminoglycans and collagen II expression, while expression





FIGURE 1 | Chondrosarcoma 14 day alginate spheroid cultures were assessed for **(A)** Spheroids presented chondrosarcoma-like histology (as seen by HandE) and were positive for chondrosarcoma extracellular matrix components such as glycosaminoglycans (toluidine and alcian blue staining) **(B)** Collagen II expression was present in all three cell lines and **(C)** expression levels remained stable or increased over time ($n \geq 3$). Scale bar = 20 μ m.

was abundant in the three high grade chondrosarcoma tissue specimens (**Supplementary Figure 1**).

CH2879 exhibited high proliferative activity as shown by Ki-67 immunohistochemistry at 14 days of 3D culture (50%), whereas a smaller portion of JJ012 and SW1353 cultures was proliferative at this stage (8 and 11%) (**Figures 2A,B**). In comparison, the average proliferative activity (22.9%) was more

similar to that of chondrosarcoma tissue (25.9%) than 2D cultured cell lines (82.7%) (**Supplementary Figure 3**). Cleaved caspase-3 levels in all three cultures were relatively high (total average = 43.9%), indicating a high level of apoptosis within the 3D cultures. For comparison, the apoptotic levels in chondrosarcoma tissue were higher than in 2D cell cultures (3.2% compared to 0.3% average) but not at similar levels to our model



(**Supplementary Figure 3**). Since we previously reported IGF1R expression to be artificially upregulated in chondrosarcoma cell lines, being low to absent in chondrosarcoma primary tumor tissue but positive in 2D cultured cell lines (Peterse et al., 2016), we assessed IGF1R in the spheroids. IGF1R expression was negative in all samples (**Figure 2B**), with an adequate external positive control (**Supplementary Figure 4**).

Chondrosarcoma Spheroids Respond Differently to Antineoplastic Agents as Compared to Monolayers

In general, the 3D *in vitro* cultures were more resistant to the panel of tested compounds, as can be seen from the resulting IC_{50} values and 3D/2D ratios (**Table 1**). All three cell lines were

more resistant to doxorubicin (JJ012 3D/2D = 56.5, SW1353 3D/2D = 3.7) and cisplatin (CH2879 3D/2D = 2.9, JJ012 3D/2D = 21.6, SW1353 3D/2D = 3.8) (with the exception of CH2879 treated with doxorubicin, 3D/2D = 0.7) (**Figures 3A,B**). During temozolomide treatment, all three cell lines showed more resistance in spheroid as compared to monolayer culture (**Figure 3C**). CH2879 and JJ012 spheroids were more sensitive to ABT-737 treatment (CH2879 3D/2D = 0.4, JJ012 3D/2D = 0.7) whereas SW1353 spheroids were more resistant (3D/2D = 1.4) (**Figure 3D**). YM-155 treatment followed a similar trend to most treatments, with higher resistance to drug for all spheroid lines (CH2879 3D/2D = 1.2, JJ012 3D/2D = 10.1, SW1353 3D/2D = 11) (**Figure 3E**).

CH2879 spheroids were more sensitive to sapanisertib compared to monolayer cultures (3D/2D ratio = 0.2), while for

TABLE 1 | IC₅₀ values for 2D and 3D cultured chondrosarcoma cell lines treated with a small panel of compounds.

Compound	2D IC ₅₀			3D IC ₅₀			3D/2D ratio		
	CH2879	JJ012	SW1353	CH2879	JJ012	SW1353	CH2879	JJ012	SW1353
Cisplatin (μM)	1.48 ± 0.16	1.05 ± 0.26	4.08 ± 0.28	4.26 ± 0.68 (****)	22.64 ± 7.26 (****)	15.30 ± 4.28 (****)	2.9	21.6	3.8
Doxorubicin (nM)	334.6 ± 22.63	17.72 ± 2.87	200.2 ± 22.12	230.5 ± 32.92 (****)	1002 ± 229.3 (****)	750.6 ± 182.8 (****)	0.7	56.5	3.7
Temozolomide (μM)	2390 ± 267.9	188.8 ± 32.82	523.8 ± 63.21	n/e	2470 ± 2176 (**)	n/e	resistant 3D	13.1	resistant 3D
ABT-737 (μM)	7.95 ± 1.31	18.93 ± 3.45	14.35 ± 1.99	3.26 ± 0.57 (****)	13.42 ± 2.22 (**)	19.82 ± 5.08 (*)	0.4	0.7	1.4
YM-155 (nM)	66.12 ± 9.74	7.22 ± 1.15	3.66 ± 0.65	76.72 ± 13.69 (ns)	73.27 ± 12.25 (****)	40.37 ± 10.64 (****)	1.2	10.1	11.0
Sapanisertib (nM)	62.23 ± 5.73	15.64 ± 1.34	35.08 ± 2.02	13.52 ± 2.82 (****)	75.74 ± 16.14 (****)	113.9 ± 24.92 (****)	0.2	4.8	3.2
AGI-5198 (μM)	n/e	n/e	n/e	n/e	n/e	n/e	resistant	resistant	resistant
Dox + ABT (nM)	128.7 ± 8.11	13.36 ± 2.11	80.12 ± 6.94	68.86 ± 9.33 (****)	1092 ± 293.2 (****)	1167 ± 384.7 (****)	0.5	81.7	14.6

The 3D/2D ratio is also given representing the difference in IC₅₀ between 2D and 3D cultures. Ratio values of less than one indicate factor of higher sensitivity in 3D culture (red), values above one indicate a higher drug resistance in 3D spheroids (green) and no difference in result = 0 (yellow). If a line is unaffected by the treatment in both 2D and 3D culture it is labeled resistant, if only unaffected in 3D culture it is labeled resistant 3D. Significance was determined between 2D culture IC₅₀ and the 3D culture counterparts. Significance is interpreted as 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***), <0.0001 (****) on the 3D IC₅₀ columns. n/e= no effect.

JJ012 and SW1353 spheroids were more resistant (JJ012 3D/2D = 4.8, SW1353 3D/2D= 3.2) (Figure 3F). AGI-5198, a mutant-IDH1 inhibitor, had no significant effect on the cell lines in monolayer nor spheroids (Figure 3G).

Treatment Response at the Histological Level Is Highly Variable

Additionally to the global cell viability dose response curve data, histological analysis of treated spheroids revealed further information on different morphological effects on the spheroids. CH2879 spheroids are displayed as an example of drug effect (Figure 4). YM-155 treatment showed a reduction in number and clear loss of viability in smaller diameter spheroids, whereas larger spheroids remained proliferative (Figure 4, Supplementary Figure 5). On the other hand, cisplatin treated spheroids showed a more global chemotherapy effect, with an overall decrease in spheroid size and number. The majority of ABT-737 spheroids were showing signs of apoptosis (shrunken nuclei and cleaved caspase-3 positivity) (Figure 4).

CS Spheroid Model Can Be Used to Evaluate Synergy

Chondrosarcoma spheroids were also utilized for prediction of synergy. As demonstrated by combining doxorubicin and ABT-737 the excess over Bliss values, indicating synergy, also differ between the monolayer and spheroid cultures (Figure 5). The combination of Bcl-2 inhibition using ABT-737 and doxorubicin was previously shown to reduce cell viability *in vitro* by inducing apoptosis and overcoming chemoresistance (van Oosterwijk et al., 2011). Synergy is less pronounced in CH2879 spheroids compared to 2D (Excess over Bliss= 22 vs. 13%) and combination was only additive for JJ012 (Excess over Bliss = 5 vs. 0%) and SW1353 (Excess over Bliss = 23 vs. 0%) spheroids (Figure 5C). Although around 10% of total spheroids were still viable, as indicated by presto blue assay, even at 1 μM doxorubicin; histological analysis showed a higher amount of cell death in


remaining spheroids for all three cell lines compared to single-agent options (Figures 3A,D, 5A,B).

CS Spheroid Model Can Be Used for Long-Term Treatment

Sapanisertib, an mTOR inhibitor, was initially used for 3 day treatment of mature 14 day old spheroids. All three cell lines were sensitive to the treatment, similar to previously published 2D results (Table 1) (Figure 3F) (Addie et al., 2019). For long-term treatment, two doses of sapanisertib were given overall throughout spheroid growth, one at day one and one at day eight. Cell viability response measured at 7 day and 14 day treatment with sapanisertib did not significantly differ from response to 3 day treatment of mature spheroids for any of the three cell lines tested (Figure 6A), however a trend toward higher resistance to sapanisertib in two out of three mature cultures was observed (Figure 6B). These results show that our model is suitable for up to 14 days of treatment, but that in case of sapanisertib, increase in treatment length and number of doses do not lead to lower cell viability. CH2879 fold change in cell viability at 10 nM sapanisertib treatment shows an initial delay in growth at 1 week of treatment compared to control culture followed by an increase in growth rate by 2 weeks, which may suggest outgrowth of a resistant cell population (Figure 6C). Similar trends were observed with the other two cell lines (Supplementary Figure 6). This was confirmed by histological analysis which indicated presence of unaffected, slightly more proliferative spheroids in the treated group (65.63% Ki-67 positive cells compared to 52.32%) (Figure 6D). The remaining spheroids were also shown to have normal expression of pS6, the activated form of a kinase downstream of mTOR, after mTOR inhibition (Figure 6D).


CS Spheroid Model Allows for Direct Assessment of Radiation Response

Colony formation assays are typically employed to observe sensitivity to radiotherapy (Franken et al., 2006). This method



is dependent on the cell clonogenic capacity, which is reduced after irradiation. As the spheroids produced using our method are clonal and cells cannot migrate freely within the scaffold, we adapted the colony formation assay for 3D. Significant changes in the surviving fraction after 2Gy (SF2) treatment are considered indicative of the *in vivo* response to radiotherapy (Fertil and

Malaise, 1981). CH2879 spheroids appear to be the most sensitive to radiotherapy (SF2 = 0.58) and JJ012 and SW1353 spheroids only have a small reduction in clonogenic capacity (SF2 = 0.83 and 0.95, respectively) (Figure 7B). The number of spheroids as well as their size is reduced with increased radiation dose for all three chondrosarcoma cell lines, with CH2879 shown




as a histological example (Figures 7A,B). Size of colonies as well as surviving fraction is reduced with increased irradiation (Figure 7C).

DISCUSSION

Although cell lines cultured in monolayer are easy to work with, they do not adequately mimic the morphology and the behavior of tumor cells in patients (Horvath et al., 2016). For rare cancers, representative *in vitro* models are especially needed in order to adequately predict which compounds could provide patient benefit, as organizing clinical trials for rare cancer patients is challenging. In this paper we developed a more representative model for conventional chondrosarcoma of bone.

To date, chondrosarcoma cell lines have been cultured in 3D using non-adherent surfaces (van Oosterwijk et al., 2012b), the hanging drop method (Perut et al., 2018), collagen scaffolds (Truong et al., 2012; Hamdi et al., 2015) and alginate beads (Lhuissier et al., 2017). The attachment prevention techniques used succeeded in formation of large regular multicellular tumor spheroids (MCTS) with corresponding representative regions of quiescence, hypoxia and necrosis, whereas cells within the collagen gel model migrated throughout the gel and oxygen levels were regulated externally in order to mimic *in vivo* hypoxic circumstances (van Oosterwijk et al., 2012b; Hamdi et al., 2015). Use of scaffolds such as alginate, containing a mechanical strain component but where migration is limited, may be beneficial for the 3D culture of sarcoma.



Morphological features similar to high grade chondrosarcoma could be observed from H&E stained spheroids and extracellular matrix components were highlighted using histological and immunohistochemical means, allowing for a suitable comparison to observations in patients. The straightforward application of methods conventionally used to assess patient tissue samples is a major advantage of 3D culture over 2D models. The development of 3D cultures for mesenchymal tumors requires a different approach as compared to the more frequent epithelial cancers, as many sarcomas are characterized by the deposition of extracellular matrix, including collagen, hyaluronan and glycoproteins. Thus, 3D sarcoma models should facilitate matrix deposition by the tumor cells, over a short culture period. Presence of glycosaminoglycan and collagen II in all chondrosarcoma cell line spheroids confirmed the deposition of a chondroid matrix, which increases model similarity to *in vivo* (Aigner et al., 1997). Moreover, levels of IGF1R, that we previously showed to be artificially upregulated during culture in 2D, were negative in the spheroids, also indicating a higher similarity to chondrosarcoma *in vivo* (Peterse et al., 2016). Culture induced upregulation of genes or pathways will affect drug response, and use of the spheroid model will reduce the number of artificially upregulated targets.

Of note, there was a high level of apoptosis observed within the spheroids, which may be a reflection of tissue remodeling related programmed cell death, which is normal for a large cell mass. This was also reported by others (Lhuissier et al., 2017). The alginate scaffold is highly biocompatible and is therefore unlikely to be the cause of apoptosis, as it has been previously used for many cell-based applications (Andersen et al., 2015). Moreover, cells are unable to migrate through the alginate, and dead cells or debris would remain trapped. All of the cultures maintained proliferation at 14 days of culture at similar levels to *in vivo* on average, indicating a sufficient continuation of cell growth during the therapeutic treatment period, and we showed that long-term treatment is feasible.


Overall, response to chemo- and radiation therapy in 3D chondrosarcoma spheroids were more in line with results *in vivo* as compared to monolayer (Table 2). Generally, higher

resistance to classical chemotherapeutics, such as doxorubicin, cisplatin and temozolomide was observed. These results are in line with current *in vivo* and clinical data (Table 2) as conventional chemotherapy is not effective as single-agent treatment for chondrosarcoma (Skubitz, 2003; Italiano et al., 2013; van Maldegem et al., 2019). The increased resistance in 3D might be explained by the presence of matrix components, pH and oxygen gradients as well as lowered exposure to therapy within spheroid cultures compared to monolayer, where all cells are equally fully exposed. There were also some exceptions where response in 3D and monolayer did not significantly differ, such as doxorubicin treated CH2879.

We cannot exclude that the different growth rates of the various cell lines affect response in the spheroid model. For example, doxorubicin is known to preferentially affect proliferating cells (Yang et al., 2014), therefore this could be a contributing factor to the maintained sensitivity of CH2879 spheroids to this drug, since the amount of proliferation observed by immunohistochemistry was higher in this cell line. However, overall CH2879 growth, observed by presto blue assay, was comparable to JJ012 during the 72 h treatment period, yet the JJ012 spheroids were notably more resistant to doxorubicin than monolayer cultures (2D/3D 49.6). Therefore, growth rate may not be the only contributing factor.

Growth rate dependent variation between cell lines in 2D is commonly corrected for by using a metric such as the GR₅₀. This metric relies on the assumption that the cells are in exponential growth before and during application of the drug, otherwise a reliable value cannot be achieved (Brooks et al., 2019). Applying these metrics to 3D cell culture models is more difficult, since these tend to have significantly slower growth rates. Therefore, in 3D, when cell growth rate is not high enough for GR₅₀ calculation, differences between cell lines should still be considered separately, when observing the data by comparing the viability of control samples before and after the treatment period.

An advantage of the 3D alginate spheroid model is that in addition to monitoring cell viability, it enables morphological and immunohistochemical assessment after treatment. We previously used an siRNA screen and identified survivin as



a potential target for treatment in chondrosarcoma (de Jong et al., 2016b). Here our previous results are confirmed as the survivin inhibitor YM-155 also reduced cell viability in the chondrosarcoma spheroids. However, while 2D results suggested a relation between p53 mutation status and response, this was not confirmed in the 3D spheroid model. The lack of a complete reduction in viability could also be due to reduced exposure of the cells to YM-155. Histological evaluation revealed that the spheroids which remained viable and proliferative were larger in size. Post-treatment spheroid colony number and size evaluation showed a reduced presence of smaller spheroids after

treatment and no visible difference to larger spheroids. An increase in apoptosis was not observed after treatment with YM-155, which was consistent with previous data where we showed that YM-155 affected cell cycle progression. Previously published data on YM-155 sensitivity of a large panel of cancer cell lines indicated that resistance may also be associated with low SLC35F2 expression, therefore before moving onto *in vivo* testing expression of this efficacy biomarker could be studied within chondrosarcoma spheroids (Winter et al., 2014).

The anti-apoptotic Bcl-2 family members were earlier shown to be overexpressed and to play an important role in chemo




FIGURE 7 | Chondrosarcoma spheroids were irradiated with indicated doses and response evaluated by 3D colony formation assay ($n = 4$). **(A)** All three cell lines were sensitive to radiation at higher dosages (>2Gy), however CH2879 also showed sensitivity at lower doses (SF2 = 0.58). **(B)** CH2879 spheroid colony number and size decrease with increased radiation dose **(C)** Spheroid area (size) was also reduced with increased dose.

resistance of chondrosarcoma (de Jong et al., 2018). Restoration of the apoptotic machinery, by inhibiting the Bcl-2 family members using ABT-737, induced apoptosis and reverted the resistance of chondrosarcoma cells to doxorubicin (van Oosterwijk et al., 2012b). In the present study, ABT-737 reduced cell viability and induced apoptosis in a majority of chondrosarcoma spheroids, although a limitation of this model is the presence of a moderate apoptotic signal in control

samples. However, the synergy between doxorubicin and ABT-737 observed in monolayer cultures could not be confirmed in spheroids and IC_{50} values were increased in comparison to doxorubicin alone. By adjusting dosage amount and times, the synergistic effect could be improved. Therefore, in future experiments, synergistic effects should also be tested within spheroid models for a more representative result and refined dosing schedules.

TABLE 2 | Summary of the sensitivity of 2D, 3D *in vitro*, mouse *in vivo* conventional chondrosarcoma models to selected chemo-/radio-/targeted therapies.

Compound	Cell lines 2D	Cell lines 3D	Animal model	Patient data	Ongoing clinical trials
Cisplatin	Sensitive* (de Jong et al., 2018)	More resistant* (Lhuissier et al., 2017)	Not performed	Considered resistant. Used in combination with doxorubicin, never as single agent. Increased PFS associated with combination treatment ($n = ?/21^{\dagger}$, $n = 4$) (Italiano et al., 2013; van Maldegem et al., 2019)	Combination of cisplatin with FT 2102 recruiting (NCT03684811)
Doxorubicin	Sensitive* (de Jong et al., 2018)	JJ012, SW1353 more resistant, CH2879 slightly more sensitive*	Resistant (Perez et al., 2012; van Oosterwijk et al., 2015)	Efficacy low in conventional chondrosarcoma, even when using liposomal version. PFS longer when combined with other agents ($n = ?/32^{\dagger}$, $n = 2$, $n = 1$) (Skubitz, 2003; Italiano et al., 2013; van Maldegem et al., 2019)	Combination of doxorubicin with nilotinib ongoing (NCT02587169)
Temozolomide	JJ012 and SW1353 sensitive, CH2879 resistant*	More resistant*	Not performed	n/a	Tested as treatment for advanced sarcoma trial ongoing (NCT00003718)
AGI-5198	Resistant*	Resistant*	Not performed	Poor PFS with IDH-1 inhibitor single-agent therapy ($n = 3$) (van Maldegem et al., 2019). Six month PFS rate of 53.8% and stable disease observed in 52% of patients ($n = 13$) (Tap et al., 2020)	n/a
ABT-737	Sensitive* (van Oosterwijk et al., 2011)	SW1353 more resistant, CH2879, JJ012 more sensitive*	Not performed	n/a	n/a
Dox + ABT-737	Synergistic* (van Oosterwijk et al., 2011)	Overall loss of synergy*	Not performed	n/a	n/a
YM-155	Sensitive* (de Jong et al., 2016b)	More resistant*	Not performed	n/a	n/a
Sapanisertib	Sensitive* (Addie et al., 2019)	CH2879 more sensitive, JJ012 and SW1353 more resistant*	Delayed tumor growth, development of resistance (Addie et al., 2019)	Unclear (Chawla et al., 2018; Trucco et al., 2018)	Combination of mTOR inhibition with cyclophosphamide/nivolumab recruiting (NCT02821507, NCT03190174)
Radiation	Resistant* (de Jong et al., 2019; Venneker et al., 2019)	JJ012 more resistant, CH2879 and SW1353 comparable*	Not performed	In two retrospective studies: Advanced modality radiation treatment and higher dose treatment associated with improved survival in positive margin patient cohort ($n = ?/680^{\dagger}$) (Catanzano et al., 2019). For patients who had locally advanced disease without metastases, radiotherapy was associated with a survival benefit ($n = 45$) (Van Maldegem et al., 2014). Proton therapy resulted in ($n = ?/71^{\dagger}$) 94.1% 7-year OS in low-grade CS (Weber et al., 2016)	Advanced radiotherapy strategies for unresectable tumor trials recruiting using proton (NCT01449149) or stereotactic (NCT04098887) radiotherapy.

Clinical trials, past results and ongoing studies, are also mentioned within the summary when applicable.

*Current paper.

[†] Unknown number of conventional CS subtype within cohort.

A previously performed metabolic compound screen revealed an mTOR inhibitor, sapanisertib, as an effective anti-proliferative agent for chondrosarcoma. Reduction of oxidative and glycolytic metabolism and decreased proliferation was observed with treatment as well as a 5 day delay of tumor growth in a chondrosarcoma xenograft model (Addie et al., 2019). For comparison with xenograft results, a protocol for long-term drug treatment in spheroids was established. Reduced growth

rate was observed between 1 and 7 days of treatment with 10 nM sapanisertib, in comparison to untreated controls, which then increased between 7 and 14 days in all cell lines, in line with *in vivo* data. A phosphokinase downstream of mTOR, pS6, was still expressed in spheroids after treatment, similarly to the xenograft model, suggesting the presence of a resistance mechanism. Previously published monolayer cultures, conversely, demonstrated inhibited pS6 expression

after treatment with sapanisertib, which indicates that, in the context of the mTOR pathway, the spheroid model was more representative of *in vivo* results. Subsequently, mTOR inhibition would have a higher effectiveness as part of a combination treatment which would eliminate the remaining cell population (Boehme et al., 2018). In clinic, no significant single-agent mTOR treatment effect has been observed in chondrosarcoma patients thus far. A phase II study using ridaforolimus, another mTOR inhibitor, as a single agent did not have a noted effect on chondrosarcoma patients in the cohort (Chawla et al., 2018). However, prolonged stable disease was achieved for chondrosarcoma patients by combining mTOR inhibitors with liposomal doxorubicin or EGFR, IGF1R, VEGF inhibitors (Katz et al., 2016; Liu et al., 2016; Trucco et al., 2018; Vlahovic et al., 2018).

High hopes for effective therapy came with the identification of specific driver mutations in the isocitrate dehydrogenase genes IDH1 and IDH2, and the development of a specific inhibitor of mutant IDH1, such as AGI-5198. However, *in vitro* studies showed loss of clonogenic capacity only after long-term treatment with high concentrations (20 μ M), while no effect was observed at lower concentrations or shorter treatment times (Li et al., 2015; Suijker et al., 2015). The spheroid model also did not show loss of viability due to IDH mutant inhibitor treatment. A more metabolically stable version of the inhibitor, ivosidenib (AGI-120), was approved for chondrosarcoma clinical trials (Popovici-Muller et al., 2018) and showed poor progression free survival with single-agent therapy in one retrospective study (van Maldegem et al., 2019), and more durable disease control in a phase I study, with 52% of patients experiencing stable disease. However, a placebo controlled randomized phase II study with saridegib (IPI-926) stopped for futility after an interim-analysis (Bussiness Wire, 2020). The company never released the data for a formal scientific publication.

The effect of radiotherapy on chondrosarcoma monolayer models varied between cell lines in several studies (de Jong et al., 2019; Venneker et al., 2019). A special protocol for a 3D version of the commonly used colony formation assay was developed using the effect of radiation on spheroid number and size. This method is not possible within all 3D models as some scaffolds, such as collagen-based ones, allow free migration of cells, preventing formation of individual colonies, and the ECM production capabilities of chondrosarcoma also make cell extraction from scaffolds difficult (Hamdi et al., 2015). JJ012 spheroids exhibited a higher resistance to radiotherapy than previously published 2D culture results (SF2 2D = 0.54/0.55, 3D = 0.83), whereas CH2879 showed similar survival (SF2 2D = 0.62, 3D = 0.58) and SW1353 maintained resistance to radiotherapy (SF2 2D = 1.00/0.88, 3D = 0.95) (de Jong et al., 2019; Venneker et al., 2019). Overall, all three spheroid models were substantially resistant to radiation, as is reported for chondrosarcoma in patients. Advanced radiotherapy modalities may be able to overcome the observed resistance, because radio resistance has been linked to the total radiation dose applied, and modern techniques enable the safe application of a higher total dose. Current clinical data indeed show that the use of advanced radiation modalities, such as intensity-modulated radiation therapy (IMRT), volumetric

modulated arc therapy (VMAT), stereotactic radiosurgery (SRS) and especially particle therapy (radiotherapy with protons or carbon ions) result in a trend toward improved survival with higher radiation doses applied for patients with positive margins after resection (Weber et al., 2016; Catanzano et al., 2019). Therefore, the 3D chondrosarcoma spheroid model provides an excellent model to further investigate the use of these modalities for chondrosarcoma.

CONCLUSION

Using a spheroid model of chondrosarcoma, representative of chondrosarcoma *in vivo* with regards to morphology and extracellular matrix production, we demonstrated short and long-term *in vitro* treatment strategies. This included assessment of synergistic effect and clonogenic capacity, in order to better predict *in vivo* response. Use of the alginate bead model for chemotherapeutic, radiotherapeutic and combination therapy testing would refine the selection of therapies for *in vivo* testing of chondrosarcoma. This approach is more efficient, cost effective, ethically beneficial, and may lead to discovery of novel treatment options for chondrosarcoma patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

IP optimized 3D cell cultures and IP, SV, and BA set up 2D and 3D cultures for the study. IP, SV, and BA performed antineoplastic agent experiments. IP and AV performed data analysis of cell viability assays. HG and AK performed data analysis for clinical correlation. IB performed all IHC staining. IP analyzed 3D colony counts and IHC. JB conceived and supervised the study. IP and JB wrote the manuscript. All authors read and approved final manuscript.

FUNDING

This work was financially supported by the Netherlands Organization for Scientific Research (ZON-MW VICI 170.055 to JB).

ACKNOWLEDGMENTS

We are grateful to Dr. JA Block (Rush University Medical Centre, Chicago, IL, USA), who provided us with the JJ012 cell line and Professor A Llobart Bosch (University of Valencia, Spain) for the CH2879 cell line.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmolb.2020.566291/full#supplementary-material>

REFERENCES

- Addie, R. D., de Jong, Y., Alberti, G., Kruisselbrink, A. B., Que, I., Baelde, H., et al. (2019). Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. *J. Bone Oncol.* 15:100222. doi: 10.1016/j.jbo.2019.100222
- Aigner, T., Dertinger, S., Vornehm, S. I., Dudhia, J., von der Mark, K., and Kirchner, T. (1997). Phenotypic diversity of neoplastic chondrocytes and extracellular matrix gene expression in cartilaginous neoplasms. *Am. J. Pathol.* 150, 2133–2141.
- Andersen, T., Auk-Emblem, P., and Dornish, M. (2015). 3D cell culture in alginate hydrogels. *Microarrays* 4, 133–161. doi: 10.3390/microarrays4020133
- Angelini, A., Guerra, G., Mavrogenis, A. F., Pala, E., Picci, P., and Ruggieri, P. (2012). Clinical outcome of central conventional chondrosarcoma. *J. Surg. Oncol.* 106, 929–937. doi: 10.1002/jso.23173
- Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., et al. (2017). QuPath: open source software for digital pathology image analysis. *Sci. Rep.* 7:16878. doi: 10.1038/s41598-017-17204-5
- Boehme, A. K., Schleicher, B. S., Traub, F., and Rolaufts, B. (2018). Chondrosarcoma: a rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration and therapeutic resistance. *Int. J. Mol. Sci.* 19:311. doi: 10.3390/ijms19010311
- Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., et al. (2003). Systematic discovery of multicomponent therapeutics. *Proc. Natl. Acad. Sci. U.S.A.* 100:7977. doi: 10.1073/pnas.1337088100
- Bovée, J., Bloem, J., Flanagan, A., Nielsen, G., and Yoshida, A. (2020). “Central chondrosarcoma, grades 2 and 3,” in *Pathology and Genetics of Tumours of Soft Tissue and Bone. WHO Classification of Tumours of Soft Tissue and Bone, 5th Edn*, ed A. Lazar (Lyon: IARC Press), 375–378.
- Bovée, J. V. M. G., Hogendoorn, P. C. W., Wunder, J. S., and Alman, B. A. (2010). Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. *Nat. Rev. Cancer* 10, 481–488. doi: 10.1038/nrc2869
- Brooks, E. A., Galarza, S., Gencoglu, M. F., Cornelison, R. C., Munson, J. M., and Peyton, S. R. (2019). Applicability of drug response metrics for cancer studies using biomaterials. *Philos. Trans. R. Soc. B Biol. Sci.* 374:20180226. doi: 10.1098/rstb.2018.0226
- Bussiness Wire (2020). *Infinity Stops Phase 2 Trials of Saridegib in Chondrosarcoma and Myelofibrosis*. Bussiness Wire.
- Catanzano, A. A., Kerr, D. L., Lazarides, A. L., Dial, B. L., Lane, W. O., Blazer, D. G., et al. (2019). Revisiting the role of radiation therapy in chondrosarcoma: a national cancer database study. *Sarcoma* 2019:4878512. doi: 10.1155/2019/4878512
- Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetz, S. M., Tolcher, A. W., D’Amato, G. Z., et al. (2018). Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue Sarcomas. *J. Clin. Oncol.* 30, 78–84. doi: 10.1200/JCO.2011.35.6329
- Ching, S. H., Bansal, N., and Bhandari, B. (2017). Alginate gel particles—a review of production techniques and physical properties. *Crit. Rev. Food Sci. Nutr.* 57, 1133–1152. doi: 10.1080/10408398.2014.965773
- Colella, G., Fazioli, F., Gallo, M., De Chiara, A., Apice, G., Ruosi, C., et al. (2018). Sarcoma spheroids and organoids-promising tools in the era of personalized medicine. *Int. J. Mol. Sci.* 19:615. doi: 10.3390/ijms19020615
- de Jong, Y., Ingola, M., Briaire-de Bruijn, I. H., Kruisselbrink, A. B., Venneker, S., Palubeckaitė, I., et al. (2019). Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. *Clin. Sarcoma Res.* 9:9. doi: 10.1186/s13569-019-0119-0
- de Jong, Y., Monderer, D., Brandinelli, E., Monchanin, M., van den Akker, B. E., van Oosterwijk, J. G., et al. (2018). Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. *Oncogenesis* 7:74. doi: 10.1038/s41389-018-0084-0
- de Jong, Y., van Maldegem, A. M., Marino-Enriquez, A., de Jong, D., Suijker, J., Briaire-de Bruijn, I. H., et al. (2016a). Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. *Lab. Invest.* 96, 1128–1137. doi: 10.1038/labinvest.2016.91
- de Jong, Y., van Oosterwijk, J. G., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Agrogiannis, G., Baranski, Z., et al. (2016b). Targeting survivin as a potential new treatment for chondrosarcoma of bone. *Oncogenesis* 5:e222. doi: 10.1038/oncsis.2016.33
- Fertil, B., and Malaise, E. P. (1981). Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 7, 621–629. doi: 10.1016/0360-3016(81)90377-1
- Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., and van Bree, C. (2006). Clonogenic assay of cells *in vitro*. *Nat. Protoc.* 1, 2315–2319. doi: 10.1038/nprot.2006.339
- Fromm, J., Klein, A., Baur-Melnyk, A., Knösel, T., Lindner, L., Birkenmaier, C., et al. (2018). Survival and prognostic factors in conventional central chondrosarcoma. *BMC Cancer* 18:849. doi: 10.1186/s12885-018-4741-7
- Gebauer, M., Saas, J., Sohler, F., Haag, J., Söder, S., Pieper, M., et al. (2005). Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1 β . *Osteoarthritis Cartilage* 13, 697–708. doi: 10.1016/j.joca.2005.04.004
- Gil-Benso, R., Lopez-Gines, C., López-Guerrero, J. A., Carda, C., Callaghan, R. C., Navarro, S., et al. (2003). Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. *Lab. Invest.* 83, 877–887. doi: 10.1097/01.LAB.0000073131.34648.EA
- Hamdi, D. H., Barbieri, S., Chevalier, F., Groetz, J.-E., Legendre, F., Demoor, M., et al. (2015). *In vitro* engineering of human 3D chondrosarcoma: a preclinical model relevant for investigations of radiation quality impact. *BMC Cancer* 15:579. doi: 10.1186/s12885-015-1590-5
- Heiligenstein, S., Cucchiari, M., Laschke, M. W., Bohle, R. M., Kohn, D., Menger, M. D., et al. (2011). *In vitro* and *in vivo* characterization of nonbiomedical- and biomedical-grade alginates for articular chondrocyte transplantation. *Tissue Eng. Part C Methods* 17, 829–842. doi: 10.1089/ten.tec.2010.0681
- Hogendoorn, P. C. W., Bovée, J. V. M. G., and Nielsen, G. P. (2013). “Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma,” in *World Health Organization Classification of Tumours Soft Tissue and Bone, 4th Edn*, eds C. D. M. Fletcher, J. A. Bridge, P. C. W. Hogendoorn, F. Mertens (Lyon: IARC Press), 264–268.
- Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., et al. (2016). Screening out irrelevant cell-based models of disease. *Nat. Rev. Drug Discov.* 15, 751–769. doi: 10.1038/nrd.2016.175
- Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., et al. (2013). Advanced chondrosarcomas: role of chemotherapy and survival. *Ann. Oncol.* 24, 2916–2922. doi: 10.1093/annonc/mdt374
- Jagasia, A. A., Block, J. A., Qureshi, A., Diaz, M. O., Nobori, T., Gitelis, S., et al. (1996). Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. *Cancer Lett.* 105, 91–103. doi: 10.1016/0304-3835(96)04274-7
- Katz, D., Azraq, Y., Eleyan, F., Gill, S., Peretz, T., and Merimsky, O. (2016). Pazolimimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis. *BMC Cancer* 16:616. doi: 10.1186/s12885-016-2618-1
- Lee, G. M., and Palsson, B. O. (1990). Simplified method of making alginate-polylysine microcapsules for hybridoma cell culture using RPMI 1640 medium. *Biotechnol. Tech.* 4, 341–344.
- Lee, K. Y., and Mooney, D. J. (2012). Alginate: properties and biomedical applications. *Prog. Polym. Sci.* 37, 106–126. doi: 10.1016/j.progpolymsci.2011.06.003
- Lhuissier, E., Bazille, C., Aury-Landas, J., Girard, N., Pontin, J., Boittin, M., et al. (2017). Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas. *BMC Cancer* 17:490. doi: 10.1186/s12885-017-3478-z
- Li, L., Paz, A. C., Wilky, B. A., Johnson, B., Galoian, K., Rosenberg, A., et al. (2015). Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells. *PLoS ONE* 10:e0133813. doi: 10.1371/journal.pone.0133813
- Liu, X., Kambrick, S., Fu, S., Naing, A., Subbiah, V., Blumenschein, G. R., et al. (2016). Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. *Oncotarget* 7, 23227–23238. doi: 10.18632/oncotarget.7594

- Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., and Tsuchiya, H. (2019). Therapeutic targets for bone and soft-tissue sarcomas. *Int. J. Mol. Sci.* 20:170. doi: 10.3390/ijms20010170
- Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A., Kuijjer, M. L., Oosting, J., et al. (2011). Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in oller disease and maffucci syndrome. *Nat. Genet.* 43, 1256–1261. doi: 10.1038/ng.1004
- Perez, J., Decouvelaere, A. V., Pointecouteau, T., Pissaloux, D., Michot, J. P., Besse, A., et al. (2012). Inhibition of chondrosarcoma growth by mTOR inhibitor in an *in vivo* syngeneic rat model. *PLoS ONE*. 7:e32458. doi: 10.1371/journal.pone.0032458
- Perut, F., Sbrana, F. V., Avnet, S., De Milito, A., and Baldini, N. (2018). Spheroid-based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma. *J. Orthop. Res.* 36, 2305–2312. doi: 10.1002/jor.23880
- Peterse, E. F. P., Cleven, A. H. G., De Jong, Y., Briaire-de Bruijn, I., Fletcher, J. A., Danen, E. H. J., et al. (2016). No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. *BMC Cancer* 16:475. doi: 10.1186/s12885-016-2522-8
- Popovici-Muller, J., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J., et al. (2018). Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. *ACS Med. Chem. Lett.* 9, 300–305. doi: 10.1021/acsmchemlett.7b00421
- Rey-Rico, A., Klich, A., Cucchiari, M., and Madry, H. (2016). Biomedical-grade, high mannuronic acid content (BioMVM) alginate enhances the proteoglycan production of primary human meniscal fibrochondrocytes in a 3-D microenvironment. *Sci. Rep.* 6:28170. doi: 10.1038/srep28170
- Scully, S. P., Berend, K. R., Toth, A., Qi, W. N., Qi, Z., and Block, J. A. (2000). Interstitial collagenase gene expression correlates with *in vitro* invasion in human chondrosarcoma. *Clin. Orthop. Relat. Res.* 2000, 291–303. doi: 10.1097/00003086-200007000-00038
- Skubitz, K. M. (2003). Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma*. *Cancer Invest.* 21, 167–176. doi: 10.1081/CNV-120016412
- Suijker, J., Oosting, J., Koornneef, A., Struys, E. A., Salomons, G. S., Schaap, F. G., et al. (2015). Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. *Oncotarget* 6, 12505–12519. doi: 10.18632/oncotarget.3723
- Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., et al. (2020). Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. *J. Clin. Oncol.* 15, 1693–1701. doi: 10.1200/JCO.19.02492
- Trucco, M. M., Meyer, C. F., Thornton, K. A., Shah, P., Chen, A. R., Wilky, B. A., et al. (2018). A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. *Clin. Sarcoma Res.* 8:21. doi: 10.1186/s13569-018-0107-9
- Truong, H. H., de Sonnevile, J., Ghotra, V. P. S. S., Xiong, J., Price, L., Hogendoorn, P. C. W. W., et al. (2012). Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. *Biomaterials* 33, 181–188. doi: 10.1016/j.biomaterials.2011.09.049
- van Maldegem, A., Conley, A. P., Rutkowski, P., Patel, S. R., Lugowska, I., Desar, I. M. E., et al. (2019). Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. *Oncologist* 24, 110–116. doi: 10.1634/theoncologist.2017-0574
- Van Maldegem, A. M., Gelderblom, H., Palmerini, E., Dijkstra, S. D., Gambarotti, M., Ruggieri, P., et al. (2014). Outcome of advanced, unresectable conventional central chondrosarcoma. *Cancer*. 120, 3159–3164. doi: 10.1002/cncr.28845
- van Oosterwijk, J. G., de Jong, D., van Ruler, M. A. J. H., Hogendoorn, P. C. W., Dijkstra, P. D. S., van Rijswijk, C. S. P., et al. (2012a). Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. *BMC Cancer* 12:375. doi: 10.1186/1471-2407-12-375
- van Oosterwijk, J. G., Herpers, B., Meijer, D., Briaire-de Bruijn, I. H., Cleton-Jansen, A. M., Gelderblom, H., et al. (2011). Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma *in vitro*: BCL-2 family members cause chemoresistance. *Ann. Oncol.* 23, 1617–1626.
- van Oosterwijk, J. G., Herpers, B., Meijer, D., Briaire-de bruijn, I. H., Cleton-jansen, A. M., Gelderblom, H., et al. (2012b). Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma *in vitro*: BCL-2 family members cause chemoresistance. *Ann. Oncol.* 23, 1617–1626. doi: 10.1093/annonc/mdr512
- van Oosterwijk, J. G., Plass, J. R. M., Meijer, D., Que, I., Karperien, M., and Bovée, J. V. M. G. (2015). An orthotopic mouse model for chondrosarcoma of bone provides an *in vivo* tool for drug testing. *Virchows Archiv.* 466, 101–109. doi: 10.1007/s00428-014-1670-y
- van Praag, V. M., Rueten-Budde, A. J., Ho, V., Dijkstra, P. D. S., van der Geest, I. C., Bramer, J. A., et al. (2018). Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. *Surg. Oncol.* 27, 402–408. doi: 10.1016/j.suronc.2018.05.009
- Venneker, S., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., de Jong, Y., van Wijnen, A. J., Danen, E. H. J., et al. (2019). inhibition of PARP sensitizes chondrosarcoma cell lines to chemo- and radiotherapy irrespective of the IDH1 or IDH2 mutation status. *Cancers* 11:1918. doi: 10.3390/cancers11121918
- Vlahovic, G., Meadows, K. L., Hatch, A. J., Jia, J., Nixon, A. B., Uronis, H. E., et al. (2018). A phase I trial of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus (RAD001) and panitumumab in patients with advanced cancer. *Oncologist* 23, 782–790. doi: 10.1634/theoncologist.2016-0377
- Weber, D. C., Malyapa, R., Albertini, F., Bolsi, A., Kliebsch, U., Walser, M., et al. (2016). Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. *Radiother. Oncol.* 120, 169–174. doi: 10.1016/j.radonc.2016.05.011
- Winter, G. E., Radic, B., Mayor-Ruiz, C., Blomen, V. A., Trefzer, C., Kandasamy, R. K., et al. (2014). The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. *Nat. Chem. Biol.* 10, 768–773. doi: 10.1038/nchembio.1590
- Yang, F., Teves, S. S., Kemp, C. J., and Henikoff, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. *Biochim. Biophys. Acta* 1845, 84–89. doi: 10.1016/j.bbcan.2013.12.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Palubeckaitė, Venneker, Briaire-de Bruijn, van den Akker, Krol, Gelderblom and Bovée. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.